NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
0.6000
-0.0436 (-6.77%)
Jun 13, 2025, 4:00 PM - Market closed

Company Description

NovaBay Pharmaceuticals, Inc. does not have significant operations.

Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally.

The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.

NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals logo
Country United States
Founded 2000
IPO Date Oct 26, 2007
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Justin Hall

Contact Details

Address:
2000 Powell Street, Suite 1150, eleventh floor
Emeryville, California 94608
United States
Phone 510 899 8800
Website novabay.com

Stock Details

Ticker Symbol NBY
Exchange NYSEAMERICAN
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001389545
CUSIP Number 66987P201
ISIN Number US66987P4090
Employer ID 68-0454536
SIC Code 2834

Key Executives

Name Position
Justin M. Hall Esq., J.D. President, Chief Executive Officer, General Counsel, Chief Compliance Officer, Corporate Secretary and Director
Tommy Law Controller, Interim Chief Financial Officer and Treasurer

Latest SEC Filings

Date Type Title
Jun 4, 2025 SCHEDULE 13D Filing
May 15, 2025 10-Q Quarterly Report
May 15, 2025 SCHEDULE 13G/A Filing
Apr 22, 2025 8-K Current Report
Apr 2, 2025 10-K Annual Report
Apr 1, 2025 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 19, 2025 DEF 14A Other definitive proxy statements
Mar 11, 2025 8-K Current Report
Mar 7, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 7, 2025 8-K Current Report